Stock Market Reviews

Read and share opinions on ENVB (Enveric Biosciences, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

Latest News

• Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
  Nov 14, 2025
• Enveric Biosciences Announces Reverse Stock Split
  Oct 23, 2025
• Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
  Oct 16, 2025
• Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal
  Oct 15, 2025
• Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
  Oct 15, 2025
• Enveric Biosciences to Explore Digital Asset Treasury Opportunities
  Oct 14, 2025
• Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
  Oct 2, 2025
• Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
  Sep 18, 2025
• Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
  Sep 17, 2025
• Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
  Sep 17, 2025
• Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
  Sep 16, 2025
• Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
  Sep 3, 2025
• Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
  Sep 2, 2025
• Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
  Aug 28, 2025
• Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
  Aug 14, 2025
• Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
  Jul 23, 2025
• Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
  Jul 15, 2025